DAC Patient Recruitment Begins Second Term as Global Impact Partner With the Society for Clinical Research Sites

DALLAS (July 21, 2015)—DAC Patient Recruitment Services, an Imperial company and leader in patient recruitment and retention for clinical trials, has renewed its commitment to the Society for Clinical Research Sites (SCRS) as a Global Impact Partner (GIP) for a second term. In this role, DAC will continue to serve on the SCRS Global Impact Board at an executive level and work closely with the SCRS Leadership Council on its strategic initiatives to support the interests of the clinical research site community internationally. “We at DAC are fortunate to have the privilege of working with sites and sponsors on a daily basis,” said Steve Swanson, DAC chief executive officer and GIP board representative. “SCRS is a key component in allowing us more insight into the site perspective. Our support and participation as a Global Impact Partner further expand our commitment to the clinical trial industry and allows us to play a bigger role in assuring sites have an increasing voice in issues that impact our industry, as well as providing access to best-practices resources.” “SCRS cheers DAC’s ongoing and deepening commitment to the importance of their collaboration with sites through their relationship with SCRS,” said Christine Pierre, SCRS president. The GIP board is made up of 12 industry organizations that collaborate with SCRS during two-year terms to promote the interests of clinical trial sites on such matters as operational management, contracts and subject recruitment and retention. Each organization selects one executive level team member to serve on the board. About SCRS SCRS is a global trade organization founded in 2012, which represents more than 2,600 research sites, including 30,000 research professionals in 42 countries. The SCRS’s mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites, as well as companies that sponsor or support the work conducted at clinical research sites, will benefit from membership and sponsorship. Visit www.MySCRS.org. About DAC DAC Patient Recruitment Services is proud to be a part of the Imperial Family of Companies—a clinical research support organization also comprising ClinicaLingua Translation Services and Imperial Graphics. Together, these three vertically integrated brands focus on patient recruitment, translation services, and site material production, fulfillment and global distribution. Working in synergy with our sister companies, we provide start-to-finish clinical trial solutions with the power of three companies through the convenience of one contact and one contract. www.dacprs.com | 800.451.0322 For more information, contact: Brandon Bissell (616) 784-0100 [email protected]s.com

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.